Morepen Laboratories Ltd

Morepen Labs. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Morepen Laboratories Ltd

₹ 44.9 -1.04%
04 Jun - close price
morepen.com BSE: 500288 NSE: MOREPENLAB
About

Morepen Laboratories Ltd is engaged in the business of manufacturing, producing, developing and marketing a wide range of Active Pharmaceutical Ingredients (APIs), branded and generic formulations and also the Home Health products.[1]

Key Points

Market Leadership
The company is a leader in the pharmaceutical and medical devices industry, holding the top position in 6 APIs with the following market shares as of H1 FY25:
Montelukast (anti-asthmatic): 70%
Loratadine (anti-allergy): 69%
Desloratadine (anti-allergy): 49%
Fexofenadine (anti-allergy): 31%
Atorvastatin (cholesterol reducer): 20%
Rosuvastatin (cholesterol reducer): 19%
Additionally, it is a leader in other products including Sitagliptin, Linagliptin, Dapagliflozin, etc. [1] [2]

Website BSE NSE
  • Market Cap ₹ 2,465 Cr.
  • Current Price ₹ 44.9
  • High / Low ₹ 70.5 / 33.0
  • Stock P/E 37.8
  • Book Value ₹ 22.7
  • Dividend Yield 0.45 %
  • ROCE 7.65 %
  • ROE 5.38 %
  • Face Value ₹ 2.00
Edit ratios

Pros

Cons

  • The company has delivered a poor sales growth of 8.61% over past five years.
  • Company has a low return on equity of 9.01% over last 3 years.
  • Dividend payout has been low at 9.13% of profits over last 3 years

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare BSE 1000

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
337 369 381 395 393 386 384 403 382 391 370 458 463
321 344 352 344 336 337 341 372 352 372 342 416 440
Operating Profit 15 25 30 51 56 49 43 32 30 19 28 42 23
OPM % 4% 7% 8% 13% 14% 13% 11% 8% 8% 5% 8% 9% 5%
3 2 3 4 4 3 5 5 3 4 6 4 9
Interest 1 0 0 2 1 1 1 1 4 4 4 4 4
Depreciation 5 5 5 6 7 4 4 5 12 8 11 10 1
Profit before tax 13 22 27 47 53 47 43 30 17 11 19 31 28
Tax % 21% 27% 27% 25% 24% 26% 26% 25% 31% 29% 24% 25% 27%
10 16 20 35 40 35 32 23 12 8 14 24 20
EPS in Rs 0.20 0.31 0.39 0.69 0.78 0.69 0.58 0.41 0.22 0.15 0.26 0.43 0.37
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
370 452 548 561 717 792 1,112 1,449 1,339 1,538 1,555 1,681
324 388 487 501 652 728 1,000 1,320 1,262 1,376 1,401 1,569
Operating Profit 47 64 60 60 65 64 112 129 77 162 153 112
OPM % 13% 14% 11% 11% 9% 8% 10% 9% 6% 11% 10% 7%
1 -3 4 4 4 9 12 10 6 13 16 23
Interest 9 10 7 4 2 2 2 -7 2 4 7 16
Depreciation 39 35 34 33 38 34 28 21 18 22 24 29
Profit before tax 1 16 23 26 29 37 94 126 63 149 138 89
Tax % 19% -1% 0% 0% 0% 14% 0% 20% 27% 26% 26% 26%
1 16 23 26 29 32 94 101 46 111 102 66
EPS in Rs 0.01 0.35 0.52 0.58 0.64 0.72 2.10 2.11 0.90 2.17 1.85 1.21
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 11% 17%
Compounded Sales Growth
10 Years: 14%
5 Years: 9%
3 Years: 8%
TTM: 8%
Compounded Profit Growth
10 Years: 12%
5 Years: -7%
3 Years: 12%
TTM: -36%
Stock Price CAGR
10 Years: 6%
5 Years: -5%
3 Years: 18%
1 Year: -30%
Return on Equity
10 Years: 11%
5 Years: 10%
3 Years: 9%
Last Year: 5%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 90 90 90 90 90 90 90 96 102 102 110 110
Reserves 103 119 134 161 188 217 355 503 678 787 1,072 1,133
200 186 168 134 139 142 17 19 25 28 96 205
106 139 155 206 203 212 385 417 300 362 444 460
Total Liabilities 500 535 548 591 619 662 848 1,033 1,106 1,279 1,721 1,908
244 216 191 182 153 135 144 156 171 217 366 403
CWIP 0 0 0 0 0 0 2 14 17 24 28 8
Investments 118 118 118 118 118 119 119 118 118 126 205 110
138 201 239 291 349 408 583 745 800 912 1,122 1,387
Total Assets 500 535 548 591 619 662 848 1,033 1,106 1,279 1,721 1,908

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
51 50 49 61 15 11 49 -69 -102 77 29 20
-30 -27 -15 -24 -10 -12 -69 -23 -36 -84 -280 -119
-20 -28 -31 -38 -0 5 47 66 144 0 260 97
Net Cash Flow 1 -5 3 -1 4 3 28 -25 6 -6 9 -1
Free Cash Flow 46 43 41 37 6 -6 10 -114 -138 2 -149 -114
CFO/OP 109% 78% 81% 102% 22% 25% 44% -34% -111% 71% 42% 40%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 48 65 55 72 62 56 51 56 70 75 69 72
Inventory Days 56 53 68 79 71 93 84 95 85 85 107 53
Days Payable 124 140 126 176 123 111 95 80 86 103 127 81
Cash Conversion Cycle -21 -22 -3 -25 10 38 40 71 69 57 50 44
Working Capital Days -18 -6 -91 -66 -35 -9 16 58 105 104 122 155
ROCE % 2% 8% 8% 8% 8% 9% 21% 22% 9% 18% 13% 8%

Insights

In beta
Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Blood Glucose Monitors (Glucometers) Sold/Installed
Million Units

Log in to view insights

Please log in to see hidden values.

Login
Blood Glucose Test Strips Sold
Million Units
API Reactor Capacity
Kiloliters (KL)
API Sales Volume
Metric Tons (MT)
Blood Pressure Monitors Sold
Million Units
Drug Master Files (DMFs) Filed
Number
Total Active Patents Filed
Number
Blood Glucose Test Strips Production Capacity
Crore Units
BP Monitors Production Capacity
Lakh Units
Desloratadine API Export Market Share from India
Percentage
Glucometers Production Capacity
Lakh Units
Loratadine API Export Market Share from India
Percentage
Medical Representatives (MR) Strength
Number
Montelukast API Export Market Share from India
Percentage

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
38.22% 38.22% 38.22% 38.22% 38.22% 35.66% 35.66% 35.66% 35.66% 35.66% 35.66% 35.66%
1.00% 1.29% 2.11% 1.85% 1.67% 2.08% 2.22% 1.94% 1.72% 1.62% 1.62% 1.59%
2.32% 2.27% 2.21% 2.15% 2.14% 1.69% 1.64% 1.67% 1.50% 1.49% 1.25% 1.25%
0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01%
58.45% 58.20% 57.46% 57.76% 57.96% 60.57% 60.46% 60.72% 61.09% 61.22% 61.46% 61.50%
No. of Shareholders 3,01,8323,04,0013,04,2893,36,0193,48,7664,30,9294,48,3614,68,8604,61,1804,61,8534,53,1374,47,286

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls